1. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology. 2003. 37:961–969.
Article
2. Hernandez JL, Riancho JA, Gonzalez-Macias J. Cholangiocarcinoma presenting as Trousseau's syndrome. Am J Gastroenterol. 1998. 93:847–848.
3. Ching CK. Trousseau's syndrome in a patient with cholangiocarcinoma. Am J Gastroenterol. 1991. 86:928–929.
4. Tasi SH, Juan CJ, Dai MS, Kao WY. Trousseau's syndrome related to adenocarcinoma of the colon and cholangiocarcinoma. Eur J Neurol. 2004. 11:493–496.
Article
5. Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977. 56:1–37.
6. Trousseau A. Phlegmasia Alba Dolens. Clinique medicale de l'Hotel-Dieu de Paris, London: New Syndeham Society. 1865. 3:94.
7. Song MK, Kim YS, Lee KM, Kim SK, Chang J, Kim SK, Lee WY. A case of Trousseau's syndrome associated with lung cancer. Tuberc Respir Dis. 1995. 42:941–946.
Article
8. Nakayama M, Iha T, Kanazawa K. Unusual Trousseau' syndrome in ovarian carcinosarcoma: multiple systemic thromboembolic events. J Obstet Gynaecol. 2002. 22:699–700.
9. Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer. 1997. 80:649–655.
10. Minna JD, Bunn PA Jr. DeVita VT, Hellman S, Rosenberg SA, editors. Paraneoplastic syndromes. Cancer: principles and practice of oncology. 1989. 3rd edition. Philadelphia: JB Lippincott;1920–1940.
11. Denko NC, Giaccia AJ. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res. 2001. 61:795–798.
12. Rogers LR, Cho ES, Kempin S, Posner JB. Cerebral infarction from non-bacterial thrombotic endocarditis. Clinical and pathological study including the effects of anticoagulation. Am J Med. 1987. 83:746–756.
13. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002. 346:752–763.
Article
14. von Tempelhoff GF, Heilmann L, Hommel G. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis [letter]. Cancer Res. 2001. 61:7697–7698.
15. Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost. 2001. 27:657–666.
Article
16. Kuruvilla J, Wells PS, Morrow B, MacKinnon K, Keeney M, Kovacs MJ. Prospective assessment of the natural history of positive D-dimer results in persons with acute venous thromboembolism (DVT or PE). Thromb Haemost. 2003. 89:284–287.
Article
17. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol. 2002. 119:1005–1010.
Article
18. Proven A, Bartlett RP, Moder KG, Chang-Miller A, Cardel LK, Heit JA, Homburger HA, Petterson TM, Christianson TJ, Nichols WL. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies. Mayo Clin Proc. 2004. 79:467–475.
Article
19. Caprini JA, Glase CJ, Anderson CB, Hathaway K. Laboratory markers in the diagnosis of venous thromboembolism. Circulation. 2004. 109:Suppl 1. I4–I8.
Article
20. Zuckerman E, Toubi E, Golan TD, Rosenvald-Zuckerman T, Sabo E, Shmuel Z, Yeshurun D. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer. 1995. 72:447–451.
Article
21. Morita S, Gebska MA, Kakkar AK, Scully MF. High affinity binding of heparin by necrotic tumour cells neutralises anticoagulant activity--implications for cancer related thromboembolism and heparin therapy. Thromb Haemost. 2001. 86:616–622.
22. Zuger M, Demarmels Biasiutti F, Wuillemin WA, Furlan M, Lammle B. Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome. Ann Hematol. 1997. 75:165–167.
Article